{"blog": [], "keywords": [{"value": "Muscular Dystrophy", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Food and Drug Administration", "name": "organizations", "rank": "2", "is_major": "Y"}, {"value": "Sarepta Therapeutics Inc.", "name": "organizations", "rank": "3", "is_major": "Y"}, {"value": "Clinical Trials", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "5", "is_major": "Y"}], "web_url": "http://www.nytimes.com/2016/09/20/business/fda-approves-muscular-dystrophy-drug-that-patients-lobbied-for.html", "document_type": "article", "byline": {"person": [{"lastname": "TAVERNISE", "firstname": "Sabrina", "role": "reported", "organization": "", "rank": 1}], "original": "By SABRINA TAVERNISE"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/09/20/business/20DRUG/20DRUG-thumbWide.jpg", "legacy": {"wide": "images/2016/09/20/business/20DRUG/20DRUG-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/09/20/business/20DRUG/20DRUG-articleLarge.jpg", "legacy": {"xlarge": "images/2016/09/20/business/20DRUG/20DRUG-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 400}, {"url": "images/2016/09/20/business/20DRUG/20DRUG-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/09/20/business/20DRUG/20DRUG-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "747", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "The decision went against the recommendation of independent experts, and the agency is requiring an additional trial to confirm effectiveness.", "pub_date": "2016-09-20T04:00:00+0000", "news_desk": "Business", "headline": {"print_headline": "F.D.A. Clears Debated Drug That Patients Lobbied For", "main": "F.D.A. Approves Muscular Dystrophy Drug That Patients Lobbied For"}, "print_page": "1", "snippet": "The decision went against the recommendation of independent experts, and the agency is requiring an additional trial to confirm effectiveness....", "_id": "57e05a7b95d0e021d7987280", "slideshow_credits": null, "abstract": "Food and Drug Administration approves eteplirsen, medication for Duchenne muscular dystrophy, overriding objections by their own experts and bowing to intense patient lobbying; vote leads stock of drug maker Sarepta Therapeutics to soar. "}